Sanofi $SNY Position Lifted by Equity Investment Corp

Equity Investment Corp lifted its position in shares of Sanofi (NASDAQ:SNY) by 1.3% during the 3rd quarter, HoldingsChannel reports. The fund owned 2,636,859 shares of the company’s stock after purchasing an additional 34,888 shares during the period. Sanofi comprises approximately 1.5% of Equity Investment Corp’s portfolio, making the stock its 23rd largest holding. Equity Investment Corp’s holdings in Sanofi were worth $108,718,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Western Wealth Management LLC bought a new stake in Sanofi during the 1st quarter worth $29,000. Root Financial Partners LLC bought a new position in Sanofi in the third quarter valued at about $27,000. Signature Equity Partners LLC raised its position in Sanofi by 322.2% in the third quarter. Signature Equity Partners LLC now owns 857 shares of the company’s stock valued at $35,000 after purchasing an additional 654 shares during the last quarter. Financial Network Wealth Advisors LLC raised its position in Sanofi by 103.3% in the third quarter. Financial Network Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $38,000 after purchasing an additional 463 shares during the last quarter. Finally, Provenance Wealth Advisors LLC boosted its stake in shares of Sanofi by 359.8% during the third quarter. Provenance Wealth Advisors LLC now owns 2,322 shares of the company’s stock valued at $96,000 after purchasing an additional 1,817 shares in the last quarter. Institutional investors own 14.03% of the company’s stock.

Sanofi Stock Performance

NASDAQ SNY opened at $48.23 on Wednesday. The company has a market capitalization of $116.93 billion, a price-to-earnings ratio of 23.88, a PEG ratio of 1.32 and a beta of 0.31. The company has a quick ratio of 0.27, a current ratio of 1.12 and a debt-to-equity ratio of 0.20. Sanofi has a twelve month low of $39.07 and a twelve month high of $52.68. The stock has a fifty day simple moving average of $42.44 and a 200 day simple moving average of $44.36.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 30th. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.56 by $0.48. The firm had revenue of $17.25 billion for the quarter, compared to the consensus estimate of $14.30 billion. Sanofi had a return on equity of 15.16% and a net margin of 8.70%. The business’s quarterly revenue was up 16.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.91 EPS. Sell-side analysts expect that Sanofi will post 5.07 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on SNY. UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a research note on Thursday, September 17th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a report on Thursday, October 1st. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research report on Thursday, October 1st. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Wolfe Research assumed coverage on shares of Sanofi in a research report on Friday, October 9th. They issued a “peer perform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $53.00.

Sanofi Company Profile

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.